drugset / Trial / NCT05028504
A Phase II Study of Anlotinib Combined With Penpulimab in Subjects With Gynecological Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, open-label, phase II clinical trial to evaluate the efficacy and safety of penpulimab combined with anlotinib in subjects with gynecological cancer, including 23 ovarian cancer，37 endometrial cancer，26 cervical cancer.
Timeline
- Start
- 2022-05-10
- Primary completion
- 2024-12-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 12 mg | Oral |
| Subject | Penpulimab | Monoclonal antibody | 200 mg | Intravenous |